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Abstract
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Objective: Episodes of acute adrenal insufficiency (AI)/adrenal crises (AC) are a serious consequence
of congenital adrenal hyperplasia (CAH). This study aimed to assess morbidity from acute illness in
CAH and identify factors associated with use of IV hydrocortisone, admission and diagnosis of an
AC.

Method: An audit of acute illness presentations among children with CAH to paediatric hospitals in
New South Wales, Australia, between 2000 and 2015.

Results: There were 321 acute presentations among 74 children with CAH. Two thirds (66.7%,
n=214) of these resulted in admission and 49.2% (n=158) of the patients received intravenous (IV)
hydrocortisone. An AC was diagnosed in (9.0%). Prior to presentation, 64.2% (n=206) had used

oral stress dosing and 22.1% (n=71) had been given intramuscular (IM) hydrocortisone. Vomiting
was recorded in 61.1% (n=196), 32.7% (n=64) of whom had used IM hydrocortisone. Admission,
AC diagnosis, and use of stress dosing varied significantly between hospitals. IM use varied from
7.0% in one metropolitan hospital to 45.8% in the regional hospital. Children aged up to 12 months
had the lowest levels of stress dosing and IV hydrocortisone administration. A higher number of prior
hospital attendances for acute illness was associated with increased use of IM hydrocortisone.

Conclusion: Pre-hospital and in-hospital management of children with CAH can vary between health
services. Children under 12 months have lower levels of stress dosing prior to hospital than other age
groups. Experience with acute episodes improves self-management of CAH in the context of acute
illness in educated patient populations.

This article is protected by copyright. All rights reserved.

Introduction
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Congenital adrenal hyperplasia (CAH) is the most common cause of primary adrenal insufficiency
(AI) in children (1-3). In Australia, the estimated CAH incidence is about one in 15,000, which is
comparable to that in other countries (1-4). Approximately 95% of affected children have a deficiency
of the enzyme 21-hydroxylase from the autosomal inheritance of inactivating mutations in both
CYP21A2 alleles. This results in an impaired biosynthesis and secretion of cortisol, with or without
aldosterone deficiency, in addition to elevated levels of adrenal androgens (3,5-7). Treatment of CAH
involves the administration of glucocorticoid, both as a replacement therapy and to suppress ACTH
stimulation, thereby reducing excess adrenal androgen production (3,5,6). Fludrocortisone is also used
to treat aldosterone deficiency.
All children with CAH are at higher risk of morbidity and mortality, some of which is

attributable to potentially fatal adrenal crises (ACs) (5,6,8-10). These acute events have an estimated

incidence of between 4.9 and 10 ACs per 100 patient years (10,11). ACs are characterised by
hypotension, electrolyte abnormalities, hypoglycaemia, vomiting, abdominal pain and a reduced level
of consciousness. They occur when the physiological requirement for cortisol is greater than the
amount in the circulation, typically during periods of physiological stress, such as an infection
(1,3,5,7). Children with the more severe salt-wasting phenotypes are at a heightened AC risk. Those
with less severe forms are also vulnerable during stress due to glucocorticoid-related suppression of
the hypothalamic-pituitary axis (12).
Cortisol dose escalation is regarded as the cornerstone of AC prevention in all forms of AI,

including CAH (13-16). Parents and guardians are taught to increase their child’s dose of oral
glucocorticoid during intercurrent illness or to administer an intramuscular (IM) injection when oral
glucocorticoid therapy cannot be taken or absorbed. However, efforts by health professionals to
educate carers and patients about the importance of stress dosing have not resulted in the elimination
of ACs (17-19). Indeed, recent studies have shown that AC events continue to occur, even among
well-educated AI patients (17,18).
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The reasons for the continued incidence of ACs in children with CAH are unknown. Various
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factors other than the effectiveness of AC prevention programs, such as psychosocial and cultural
factors, health service availability, and clinical practices have been postulated but the basis for their
continued occurrence remains unclear (9,17,20,21). The aim of this study was to investigate the
frequency, causes, severity and management of acute illness in a large sample of patients with CAH
who presented to hospital.

Subjects and Methods
Three paediatric hospitals provide specialist healthcare to the 1.9 million children (22) in the state of
New South Wales, Australia on a referral basis, in addition to providing general and specialist
paediatric services to their local community. Two of these hospitals (A and B) are in metropolitan
Sydney and the third (Hospital C) is in a large regional centre. Hospitals A and B have a practice
guideline, which consists of a protocol for acute AI/AC management that includes instructions on the
immediate administration of IM or IV hydrocortisone, fluid resuscitation and specific treatment of
hypoglycaemia and abnormal electrolytes. By comparison, Hospital C uses a specific AI management
sheet for each patient that is developed by their regular paediatric endocrinologist and paediatric
endocrine nurse educator. Information on all episodes of care in these hospitals is stored according to

the patient’s medical record number (MRN) and includes demographic details; the principal
diagnosis; whether the patient was treated in Accident and Emergency only or was admitted to
hospital; and all comorbid diagnoses, which are coded according to the Australian modification of the
International Statistical Classification of Diseases and Related Problems (ICD-10) (23).
The MRNs of all children in each hospital who had at least one admission in which there was

a record of a principal or comorbid diagnosis coded under the rubric E25.0 (Adrenogenital disorders
associated with enzyme deficiency) were identified (23). All attendances at Accident and Emergency
and admissions to hospital between January 2000 and December 2015 for patients up to 18 years of
age were included. Only those children who were on glucocorticoid replacement therapy and had an
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acute medical (non-surgical) illness that resulted in an unplanned attendance at hospital were selected
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for this analysis.
All records were accessed electronically except for some of the earliest records for Hospital

B, which were paper-based. Demographic information and data on the reason for attendance, type and
length of stay, presenting symptoms and signs, diagnosis, use of stress dosing and management were
collected.
Ethics approval was granted by the Human Research and Ethics Committees of the Sydney

Children’s Hospital Network (SCHN), John Hunter Children’s Hospital, and The University of Notre
Dame, Australia.

Data management
Some symptoms were not documented in some medical records, possibly through omission. Where
this information was not found, it was assumed that the symptom was not part of that child’s
presenting problem and that symptom was classified as absent. Similarly, where there was no blood
chemistry, it was assumed that this represented a clinical decision not to take blood as the child was
relatively well and these records were coded as normal. Hypotension was classified as either a blood
pressure that was lower than the appropriate age-related boundary or a capillary return time of greater
than 3 seconds and, where these values were absent, it was considered that the blood pressure was
normal. Hyperkalaemia was defined as a serum potassium of greater than 5.0mmol/L, hyponatraemia
as a serum sodium lower than 135mmol/L and hypoglycaemia as a blood glucose of less than
3.5mmol/L (24). In this analysis, an AC, which is usually characterised by hypotension, reduced
consciousness and electrolyte abnormalities, was classified as present when this diagnosis was made
by the treating doctor and entered into the medical record (14). To add further information a variable
representing the number of typical AC symptoms for each attendance was calculated. This score
comprised a count for each of hypotension, vomiting, diarrhoea, hyperkalaemia, hyponatraemia,
hypoglycaemia, and reduced consciousness for a possible score of 7 points.

This article is protected by copyright. All rights reserved.

Stress dosing (either oral or IM) in this analysis refers to any administration prior to arrival at
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hospital. Fifty (15.6%) records did not include any information about the use of stress dosing. The
proportion of complete records differed between the hospitals, with satisfactory documentation for
96.3% (n=103) in Hospital C, 79.0% (n=124) for Hospital A and 77.2% (n=40) for Hospital B. Where
these data were missing, that record was coded as not stress dosed. One record stated that stress
dosing had been used but the type was not specified.

Statistical analysis
Chi square and independent t-tests were used to assess group differences. Stepwise logistic regression
models were developed to identify predictors of: an AC diagnosis; hospital admission; the use of any
form of stress dose; oral stress dose use only; IM hydrocortisone administration; and the use of IV
hydrocortisone in hospital. Statistical tests were conducted using SPSS (IBM SPSS Statistics for Mac,
Version 24.0, Armonk, NY, USA). A P-value of <0.05 was considered significant.

Results
There were 321 presentations for treatment of an acute medical illness by 74 children with CAH
during the study period, corresponding to a median of 3 (IQR 2-7) presentations per child. Fifty-nine
(79.9%) of these children had salt-wasting CAH. Two-thirds (66.7%, n=214) of the presentations
were to the metropolitan hospitals [157 (48.9%) to Hospital A and 57 (17.8%) to Hospital B] and the
remainder (n=107, 33.3%) were to the regional hospital (C). Two-thirds (66.4%) of the attendances
resulted in admission; IV hydrocortisone was administered to 158 (49.2%) patients; and the median
length of stay was 2 (IQR 1-3) days. An AC was recorded in 29 (9.0%) cases. There were no inhospital deaths; 8 (2.5%) children were admitted to an ICU; and one child developed a severe brain
injury following hypoglycaemic seizure at home.

This article is protected by copyright. All rights reserved.

The median age of attendees was 3 (IQR 0-7) years. More than a third (39.3%, n=126) of the
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patients were in the age group 1-4 years (Table 1). An infection was diagnosed in 42.7% (n=137),
with 52 (16.2%) having a diagnosis of gastroenteritis (Table 1). More infections were identified as
viral (34.0%, n=109) than bacterial (5.3%, n=17). Hypotension was noted in 5.9% (n=19) and 11.8%
(n=38) had reduced consciousness/unconsciousness. Hyponatraemia was more common than
hyperkalaemia (12.8%, n=41 and 6.2%, n=20 respectively). Hypoglycaemia was identified in 27
(12.4%) of the patients and a seizure was reported in 13 (4.1%). The most common symptom was
vomiting, which was reported in 196 (61.1%) of the attendances, while diarrhoea was recorded in 78
(24.3%) and a prodromal illness was noted in 189 (58.9%) (Table 1). The mean number of signs and
symptoms per presentation to hospital was 1.21±0.94 and this did not differ significantly between the
hospitals (Table 2). A diagnosis of AC was significantly associated with hypoglycaemia [24.1% (n=7)
of those with an AC compared with 6.8% without (n=20), P<0.01]; a reduced level of
consciousness/unconsciousness [36.8% (n=14) of patients with a reduced level consciousness were
diagnosed with an AC compared with 5.3% (n=15) of those without (P<0.001)] and lethargy [62.1%
(n=18) of AC patients were lethargic compared with 28.8% (n=84) of those who were not, P<0.001].
The mean number of signs and symptoms of AI was significantly higher in patients with an AC
diagnosis than those without (1.93±1.00 vs. 1.14±0.90, p<0.001).

Stress dosing was used by 64.2% (n=206) of the patients; 41.7% (n=134) used oral

glucocorticoid dose escalation only and 22.1% (n=71) used IM hydrocortisone with or without oral.
Among patients with a prodromal illness, 68.8% (n=130) used stress doses, as did 74.0% (n=145) of
those with a history of vomiting and 75.6% (n=59) of patients with diarrhoea (Table 3). One third
(32.7%, n=64) of the children with vomiting were given IM hydrocortisone prior to hospital
attendance, with 41.3% (n=81) using oral only (Table 3). Similarly, fewer patients with diarrhoea
used IM hydrocortisone (24.4%, n=19) than oral (51.3%, n=40) (Table 3). IM hydrocortisone use was
significantly associated with the diagnosis of an AC (18.3% (n=13) of patients using IM were
classified as having an AC compared with 6.4% (n=16), p<0.01). By comparison, there was no
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significant association between oral stress dose use or use of all types of stress dose and AC incidence
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(both p>0.05).
AC incidence did not differ by age group but use of stress dosing did (P<0.02), being used

most commonly in children aged 1-4 years (73.0%, n=92). By comparison, both IM and IV
hydrocortisone use varied significantly by age group (p<0.04 and <0.03, respectively), and were used
more often in older patients (Table 1). Children aged 1-4 years had the highest levels of prodromal
illness (67.5%, n=85) and the lowest proportion (58.7%, n=74) of admissions (Table 1).
Hyperkalaemia was more common in children under 12 months (17.3%, n=14) (Table 1).
Admission for acute illness and use of stress dosing varied significantly by hospital (p<0.001

and p<0.01, respectively). Hospital C admitted the largest proportion (80.4%, n=86) of patients and
had the highest proportion of patients using stress doses (75.7%, n=81) (Table 2). Patients who were
admitted had a significantly higher mean number of signs and symptoms of AI than those who were
treated as outpatients only (1.35±0.92 vs. 0.93±0.92,p<0.001) (Table 4). There were also substantial
differences between the hospitals in the use of IM hydrocortisone (p<0.001), with 45.8% (n=49) of
the patients at Hospital C using IM hydrocortisone compared with 7.0% (n=11) of the patients in
Hospital A (Table 2). This difference was maintained even when only those records in which there
was a definitive note of stress dosing were included (47.6% compared to 8.8%, p<0.01). ACs were
most commonly recorded in patients attending Hospital C (15.9%, n=17) (p<0.01) and this hospital
had the highest use of IV hydrocortisone (69.2%, n=74) (p<0.001).

Predictors of AC and CAH management
Logistic regression analysis showed that an AC diagnosis was significantly associated with two
factors: the treating hospital [Hospital B vs A: OR (95% CI) 4.42 (1.25-15.65)] and Hospital C vs A:
OR

(95%

CI)

4.63

(1.65-12.94)]

and

with

the

presence

of

a

reduced

level

of

consciousness/unconsciousness [OR (95% CI) 11.27 (4.57-27.80)] but not the number of AC signs
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and symptoms (Table 5). Admission was also significantly associated with the treating hospital;
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number of signs and symptoms [OR (95% CI) 1.64 (1.24-2.17)]; and patient age (Table 5).
The use of any type of stress management strategy (either oral or IM) prior to hospital

attendance was associated with the treating hospital; vomiting [OR (95% CI); 2.50 (1.52-4.10)]; and a
diagnosis of gastroenteritis [OR (95% CI): 2.67 (1.17-6.09)] (Table 5). By comparison, oral stress
dosing was associated with a prodromal illness [OR (95% CI) of 2.43 ( 1.49-3.96)] and hospital, with

hospitals B and C having a lower likelihood of oral stress dosed patients than hospital A (Table 5).
IM hydrocortisone use was related to the number of previous attendances for an acute illness

[(OR (95% CI) for each additional presentation: 1.11 (1.03-1.20)] but not the child’s age. It was also
predicted by a history of vomiting and gastroenteritis but was negatively associated with a history of
prodromal illness (Table 4). The treating hospital was also predictive of IM hydrocortisone use, with
the regional hospital having an OR of 9.65 (95% CI 4.43-21.00) relative to Hospital A (Table 5).
Hospital was also associated with IV hydrocortisone use [OR of 2.47 (95% CI: 1.39-4.37) for

Hospital C compared with A]. In addition, vomiting was associated with IV hydrocortisone
administration, as was the increased number of signs and symptoms of acute AI (Table 5). Increasing
age was also associated with IV hydrocortisone treatment [OR for each year of age of 1.10 (95% CI
1.04-1.16)] (Table 5).

Discussion
The results of this comprehensive study of morbidity in paediatric CAH demonstrate that affected
children experience significant illness episodes and that AC events still occur, being diagnosed in 9%
of the hospital attendees. Two-thirds of the presentations resulted in admission and IV hydrocortisone
was administered to half the children who attended hospital. Overall, glucocorticoid stress
management of any kind was used by 64.2% of the patients, with exclusively oral dose escalation
employed by 41.7% and parenteral hydrocortisone used by 22.1%. While there were some differences
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in presentation and treatment according to the age of the child, greater variation was found between
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the hospitals with regards to both pre-hospital management and in-hospital care. Use of IM
hydrocortisone was positively associated with the number of previous hospital attendances for acute
care. Treatment in hospital was successful, as there were no in-hospital deaths, although one child
sustained a neurological injury.
In this study, the incidence of ACs differed significantly between the hospitals. This variation

may be due to patient factors, severity of illness, or more probably reflects differences between
clinicians in the classification of AI-related illness as an AC. Disparities between clinicians appears
in this study to be more likely given that the symptom scores did not differ between the hospitals,
although differences in severity of individual symptoms were not assessed. The definition of an AC
has been shown to vary substantially between studies in both adult and paediatric patients,
encompassing the classification of relatively mild illness as an AC to the inclusion of only severe
episodes (9,14-16). Cardiovascular compromise, manifest by hypotension or other features of
circulatory collapse in children, is generally agreed to be the key physiological feature of an AC (1416,25). However, in this study, hypotension was not significantly associated with an AC diagnosis
and was reported in fewer than 6% of the patients. Electrolyte abnormalities and hypoglycaemia are
also common features of an AC in children (15) but there was a relatively low incidence of those in
this study. Although hypoglycaemia was found to be associated with an AC on bivariate analysis, it
was not a significant predictor of AC in multivariate logistic regression models due to its association
with reduced consciousness/unconsciousness, which was the only predictor, other than the treating
hospital, of an AC diagnosis.
Patient age was associated with the management of symptomatic AI in this study, with stress

management strategies used less commonly by parents of children under 12 months than those with
older children. Similarly, IV hydrocortisone was given less often to children in the youngest age
group than to older patients. This suggests that parents are less able to manage intercurrent illness in
their very young children and are more reliant on assistance from a health service than parents of
older children. These results are consistent with research by Fleming et al. (21), which demonstrated
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that the parent’s confidence and their ability to assess the severity of their child’s illness were integral
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to their capacity to manage an acute illness episode. Improvement in the child’s ability to articulate
their symptoms with increasing age was also found to assist the family’s management of the illness
(21). Paradoxically, there were higher rates of IV hydrocortisone use in adolescents in this study,
which may reflect non-adherence to their glucocorticoid regimens, as older children with CAH
attempt to take a greater role in managing their own treatment (2,26).
While gastroenteritis was formally diagnosed in 16.2% of the children, vomiting which is also

a symptom of symptomatic AI or an AC, was present in a substantially more (61.1%) patients and
was significantly associated with hospital admission. Previous reviews have emphasised the
importance of parenteral glucocorticoids in the context of vomiting, as this symptom can preclude or
impair the absorption of oral therapy (15-17,26). Although vomiting was a predictor of both IM and
IV hydrocortisone use in the present study, only a third (32.7%) of the children with this symptom
were given parenteral hydrocortisone prior to presentation and approximately 40% were given oral
hydrocortisone only, with some parents making repeated unsuccessful attempts at its administration.
In this analysis, a record of a prodromal illness was associated with an increased use of oral stress
dosing and a decreased use of parenteral therapy. As most of these illnesses were viral respiratory
tract infections, this is consistent with recommended practice (3,15,16,19, 27). While the estimates of
stress dosing cannot be used to infer the appropriateness of the decision in each circumstance in this
study, the lower than expected use of IM hydrocortisone in the presence of vomiting suggests that
there may be opportunities for improvement in pre-hospital management of ill children with CAH.
There were differences between the three health services with regards to the pre-hospital use

of both forms of stress dosing, particularly the use of IM hydrocortisone, in which there was a six-fold
variation in usage from 7.0% to 45.8% of the presentations. Disparities between the health services
were also observed in the use of IV hydrocortisone and the rates of hospital admission. Possible
reasons for these differences include patients presenting at different stages at each hospital or
differences in clinical practice between the hospitals. Variations in the distribution of other patient
characteristics, such as ethnicity and socioeconomic status, between the hospitals may also have
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influenced both pre-hospital management and in-hospital care but these could not be assessed in this
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analysis. Previous studies have shown differences in outcomes according to ethnicity (9), and AC
events have been found to occur even among well-educated patients (17,28). Patients at each hospital
in this study had all been given education on stress management, which typically involves instruction
on stress dosing by the treating specialist, reinforcement of the steps in AC prevention at each clinic
visit and education sessions with a specialist paediatric endocrine nurse when required. Given this, the
effect of repeated experience of attendance at the same hospital for acute care on the use of IM
hydrocortisone suggests that experience may have a positive and independent influence on
management strategies used by parents who have been given education about AC prevention. Other
health service factors, such as delays in access to definitive treatment, were not found in this study but
have been identified in other populations as barriers to the implementation of effective treatment of
acute illness in AI (14,28,29).
This study reviewed the records of all patients with at least one treatment episode in a referral

hospital over a large geographic area. Importantly, it included all attendances at Accident and
Emergency as well as all hospital admissions. This enabled the examination of variation in outcomes
and management between patient subgroups and between different health services. It is possible that
there were some presentations of children to other non-specialist hospitals during the time frame of
this study that could not be included in the study sample. However, it is likely that children who were
very unwell would have been more likely to present to a specialist service or be transferred there for
treatment and, therefore, would have been included in this dataset. In addition, the number of patients
with less severe disease or those who managed episodes of illness successfully at home could not be
determined. The AC classification used in this study was based on the clinical impression of the
attending physician and this may have introduced some measurement error into the estimate of AC
incidence. Further, although the data extracted from the record was validated in this study, not all
records were complete and this differed between the hospitals. Information regarding timeframes of
readmission was not included in this study but is important and worthy of further investigation.
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In conclusion, prevention of symptomatic AI/AC remains an issue in the management of
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patients with CAH. Importantly, the results of this investigation demonstrate that patient factors alone
are not the sole determinants of health outcomes in CAH, and that parental experience with the
management of illness influences the use of stress dosing even among well-educated patients. Finally,
these results demonstrate the value of inter-hospital comparison studies for chronic diseases, such as
CAH and emphasise the importance of the consistent, guideline based application of AC prevention
strategies and optimal hospital management.
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Table 1 Signs, Symptoms and Treatment of AI by Age Group for all Presentations to Paediatric
Referral Hospitals in NSW, 2000-2015

Category

Age Group (Yrs)
Total
(N=321)

N (%)

P value

<1

1-4

5-9

10-18

(N=81)

(N=126)

(N=56)

(N=58)

Males

178 (55.5)

57 (70.4)

60 (47.6)

27 (48.2)

34 (58.6)

<0.01

Admitted

213 (66.4)

55 (67.9)

74 (58.7)

38 (67.8)

46 (79.3)

NS

33 (40.7)

62 (49.2)

24 (42.9)

18 (31.0)

NS

52 (16.2)

13 (16.0)

17 (13.5)

14 (25.0)

8 (13.8)

NS

Diarrhoea

78 (24.3)

21 (25.9)

25 (19.8)

16 (28.6)

16 (27.6)

NS

Vomiting

196 (61.1)

40 (49.4)

86 (68.3)

39 (69.6)

31 (53.4)

<0.05

Prodromal illness

189 (58.9)

46 (56.8)

85 (67.5)

26 (46.4)

32 (55.2)

0.05

Fever

108 (33.6)

22 (27.2)

52 (41.3)

22 (39.3)

12 (20.7)

<0.05

Hypotension

19 (5.9)

3 (3.7)

4 (3.2)

7 (12.5)

5 (8.6)

NS

Dehydration

35 (10.9)

6 (7.4)

13 (10.3)

8 (14.3)

8 (13.8)

NS

Reduced level of
consciousness

38 (11.8)

3 (3.7)

23 (18.3)

6 (10.7)

5 (14.3)

<0.05

Lethargy

102 (31.8)

20 (24.7)

52 (41.3)

14 (25.0)

16 (27.6)

<0.05

41 (12.8)

13 (16.0)

16 (12.7)

7 (12.5)

5 (8.6)

NS

Diagnosis
Any Infection
Gastroenteritis

137 (42.7)

Signs and symptoms

Hyponatreamia
Hyperkalaemia

20 (6.2)

14 (17.3)

4 (3.2)

2 (3.6)

0 (0.0)

<0.01

Hypoglycaemia

27 (8.4)

5 (6.2)

14 (11.1)

5 (8.9)

3 (5.2)

NS

AC Recorded

29 (9.0)

7 (8.6)

14 (11.1)

4 (7.1)

4 (6.9)

NS

PO Stress Dosing

134 (41.7)

30 (37.0)

67 (53.2)

19 (33.9)

18 (31.0)

<0.01

IM Hydrocortisone

71 (22.1)

12 (14.8)

24 (19.0)

16 (28.6)

19 (32.8)

Any form of Stress Dosing

206 (64.2)

42 (51.9)

92 (73.0)

35 (62.5)

37 (63.8)

<0.05

IV Hydrocortisone

158 (49.2)

31 (38.3)

60 (47.6)

30 (53.6)

37 (63.8)

<0.05

Management
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Table 2 Demographic characteristics, signs, symptoms and treatment of AI by hospital for all
Presentations to Paediatric Referral Hospitals in NSW, 2000-2015

Hospital

N (%)

Category

P Value
Hospital A
(N=157)

Hospital B
(N=57)

Hospital C
(N=107)

90 (57.3)

37 (64.9)

86 (80.4)

<0.001

63 (40.1)

26 (45.6)

48 (44.9)

NS

20 (12.7)

8 (14.0)

24 (22.4)

NS

Diarrhoea

39 (24.8)

8 (14.0)

31 (29.0)

NS

Vomiting

84 (53.5)

34 (59.6)

78 (72.9)

<0.01

Prodromal illness

101 (64.3)

25 (43.9)

63 (58.9)

<0.05

Fever

58 (36.9)

18 (31.6)

32 (29.9)

NS

Hypotension

11 (7.0)

1 (1.8)

7 (6.5)

NS

Dehydration

9 (5.7)

10 (17.5)

16 (15.0)

<0.05

Reduced level of consciousness

17 (10.8)

3 (5.3)

18 (16.8)

NS

Hyperkalaemia (>5.0mmol/L)

9 (5.7)

5 (8.8)

6 (5.6)

NS

Hyponatraemia (<135mmol/L)

19 (12.1)

12 (21.1)

10 (9.3)

NS

Hypoglycaemia (<3.5mmol/L)

18 (11.5)

5 (8.8)

4 (3.7)

NS

AC Recorded

6 (3.8)

6 (10.5)

17 (15.9)

<0.01

Mean AC Signs and Symptoms (SD)

1.15 (0.96)

1.14 (0.90)

1.35 (0.93)

NS

PO Stress dosing

85 (54.1)

17 (29.8)

32 (29.9)

<0.001

IM Hydrocortisone

11 (7.0)

11 (19.3)

49 (45.8)

<0.001

Any form of Stress Dosing

96 (61.1)

29 (50.9)

81 (75.7)

<0.01

IV Hydrocortisone

62 (39.5)

22 (38.6)

74 (69.2)

<0.001

Admissions
Diagnosis
Any infection
Gastroenteritis

Signs and Symptoms

Management
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Table 3 Signs, Symptoms and Treatment of AI by Method of Stress Dosing for all Presentations to
Paediatric Referral Hospitals in NSW, 2000-2015

Method of Stress Dosing
N (%)

Category
Total

PO Route

IM Injection

Males

178

63 (35.4)

39 (21.9)

Admitted

133

79 (37.1)

53 (24.9)

Any Infection

137

59 (44.0)

39 (54.9)

……Gastroenteritis

52

22 (42.3)

22 (42.3)

Diarrhoea

78

40 (51.3)

19 (24.4)

Vomiting

196

81 (41.3)

64 (32.7)

Lethargy

102*

48 (47.1)

28 (27.5)

Hypotension

19

9 (47.4)

7 (36.8)

Fever

108*

50 (46.3)

25 (23.1)

Prodromal Illness

189*

96 (50.8)

33 (17.5)

Reduced Consciousness

38

15 (39.5)

15 (39.5)

Dehydration

35

14 (40.0)

16 (45.7)

Hyperkalaemia

20

5 (25.0)

4 (20.0)

Hyponatraemia

41

19 (46.3)

9 (22.0)

Hypoglycaemia

27

11 (40.7)

7 (25.9)

AC Recorded

29

10 (34.5)

13 (44.8)

158*

65 (41.1)

50 (31.6)

Diagnosis

Signs and Symptoms

Management
IV Hydrocortisone

*One patient had a record of stress dosing without a specification about the type of administration.
Therefore, the number of patients reporting any form of stress dosing do not correspond to the sum of
the other variables.
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Table 4 Signs, Symptoms and Treatment of AI by Admission Status for all Presentations to Paediatric
Referral Hospitals in NSW, 2000-2015

Admission

Category
N (%)

ED Attendance
Only

P Value

N (%)

Diagnosis
Any infection

81 (62.80)

48 (37.20)

NS

32 (62.70)

19 (37.30)

NS

Diarrhoea

51 (65.40)

27 (34.60)

NS

Vomiting

140 (71.40)

56 (28.60)

<0.02

Prodromal illness

126 (66.70)

63 (33.30)

NS

Fever

75 (69.40)

33 (30.60)

NS

Hypotension

12 (63.20)

7 (36.80)

NS

Dehydration

27 (77.10)

8 (22.90)

NS

Reduced level of consciousness

32 (84.20)

6 (15.80)

0.01

Hyperkalaemia (>5.0mmol/L)

14 (100.00)

0 (0.00)

<0.01

Hyponatraemia (<135mmol/L)

33 (80.50)

8 (19.50)

0.04

Hypoglycaemia (<3.5mmol/L)

22 (81.50)

5 (18.50)

NS

AC Recorded

28 (96.60)

1 (3.4)

<0.01

Mean AC Signs and Symptoms
(SD)

1.35 (0.92)

0.93 (0.92)

<0.001

IV Hydrocortisone

143 (90.50)

15 (9.50)

<0.01

PO Stress dosing

79 (59.00)

55 (41.00)

<0.02

IM Hydrocortisone

53 (74.60)

18 (25.40)

NS

Any form of Stress Dosing

133 (64.60)

73 (35.40)

NS

Gastroenteritis

Signs and Symptoms

Management
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Table 5 Odds ratios for use of Oral and IM stress dosing, IV hydrocortisone and Admission.

Variable

Wald statistic

OR

95% CI

P value

PO Use
Hospital

16.53

<0.001

A (referent)

-

-

-

-

B

6.77

0.41

0.21-0.80

<0.01

C

14.02

0.36

0.21-0.62

<0.001

12.74

2.43

1.49-3.96

<0.001

Vomiting

18.60

7.48

3.00-18.67

<0.001

Hospital

34.08

Prodromal Illness
IM Use

<0.001

A (referent)

-

-

-

-

B

4.31

2.80

1.06-7.41

<0.05

C

32.63

9.65

Prodromal Illness

7.20

0.41

0.21-0.78

<0.01

Gastroenteritis

4.71

2.34

1.09-5.03

<0.01

Number of Attendances

7.47

1.11

1.03-1.20

<0.01

Vomiting

13.16

2.50

1.52-4.10

<0.001

Hospital

7.56
-

4.43-21.00

<0.001

Any Form of Stress Dosing

A (referent)
B
C

Gastroenteritis

<0.05
-

-

-

0.59

0.31-1.12

NS

1.59

0.90-2.81

NS

5.49

2.67

1.17-6.09

<0.05

14.89

2.02

1.46-2.90

<0.001

2.63
2.51

IV Hydrocortisone Use
Number of AC Signs and
Symptoms
Hospital

13.51

0.001

A (referent)

-

-

-

-

B

0.03

0.94

0.48-1.87

NS

C

11.74

2.73

1.54-4.86

0.001

12.105

1.11

1.05-1.17

0.001

Age (years)
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Vomiting

4.51

1.97

1.05-3.69

0.034

12.01

1.64

1.24-2.17

0.001

Admission
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Number of AC Signs and
Symptoms
Hospital

10.06

<0.01

A (referent)

-

-

-

-

B

1.23

1.44

0.76-2.75

NS

C

10.00

2.60

1.44-4.70

<0.01

4.10

1.10

1.00-1.128

<0.05

Age (years)
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